TERI Company Profile

00:22 EST 12th December 2018 | BioPortfolio

News Articles [6 Associated News Articles listed on BioPortfolio]

TERI Inc.’s First Annual Horse Show Showcases Innovative Campus for Individuals with Special Needs

TERI Inc., a non-profit organization committed to empowering individuals with a wide range of developmental disabilities and their families, celebrated its inaugural Annual Horse Show in San Marcos on...

Don’t ignore incest: advice from an incest survivor

In the era of #MeToo, Missy Elliot, Whitney Houston, Tyler Perry, Oprah, Ashley Judd, Gabrielle Union, Teri Hatcher and, now, Padma Lakshmi — keeping kids safe and helping adults heal is our job as ...

Surmodics Names Teri Sides as Chief Marketing Officer

Surmodics, Inc. (NASDAQ: SRDX), a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry, announced today Teri Sides has joined Su...

European Commission Approves Merck’s DELSTRIGO™ (doravirine / lamivudine / tenofovir disoproxil fumarate), a Once-Daily Fixed-Dose Combination Tablet as a Complete Regimen and PIFELTRO™ (doravirine), an NNRTI, Both for the Treatment of HIV-1 in...

Dateline City: KENILWORTH, N.J. Approvals Based on Findings from the Pivotal Phase 3 DRIVE...

Immunomic Therapeutics Senior Vice President of R&D to Participate in Bio+Tech Conference

Sr. VP of R&D will discuss lysosomal targeting technology as applied in cancer immunotherapy Tomorrow, Teri Heiland, Ph.D., Senior Vice President of Research and De...

Immunomic Therapeutics to Present at the 2018 World Vaccine & Immunotherapy Congress

Immunomic Therapeutics, Inc. (ITI) announced today that the company will present and participate at the 2018 World Vaccine & Immunotherapy Congress West Coast, being held Nove...

Drugs and Medications [0 Results]


PubMed Articles [3 Associated PubMed Articles listed on BioPortfolio]

Comparative effectiveness of dimethyl fumarate versus fingolimod and teriflunomide among MS patients switching from first-generation platform therapies in the US.

Previous real-world comparative research of MS disease modifying therapies (DMTs) in the overall population has suggested dimethyl fumarate (DMF) to be comparable to fingolimod (FTY) and more efficaci...

Patient-reported outcomes in patients with relapsing forms of MS switching to teriflunomide from other disease-modifying therapies: Results from the global Phase 4 Teri-PRO study in routine clinical practice.

Patient-reported outcomes (PROs) can assist clinicians in understanding the impact of disease-modifying therapy (DMT) on the daily lives of patients with multiple sclerosis (MS). With an increased num...

Paper Adsorbents Remove Coomassie Blue from Gel Destain and Used Gel Stain in an Environment-Friendly Manner.

Coomassie Brilliant Blue (CBB), used to stain protein gels, is known to be toxic. Therefore, laboratories do not discard used CBB into the sink owing to the possibility of it contaminating drinking wa...

Clinical Trials [0 Results]


Companies [3 Associated Companies listed on BioPortfolio]


TERI, Inc.

GXP International

It is a sole proprietorship started by Teri Stokes, Ph.D. in March 1996. Corporate policy and computer validation for large, multi-national projects (SAP, LIMS, CDMS, AEMS) are major themes of the bus...

More Information about "TERI" on BioPortfolio

We have published hundreds of TERI news stories on BioPortfolio along with dozens of TERI Clinical Trials and PubMed Articles about TERI for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of TERI Companies in our database. You can also find out about relevant TERI Drugs and Medications on this site too.

Quick Search


Corporate Database Quicklinks

Searches Linking to this Company Record